Fermata Advisors LLC Has $108,000 Stake in enVVeno Medical Corporation (NASDAQ:NVNO)

Fermata Advisors LLC raised its position in enVVeno Medical Corporation (NASDAQ:NVNO) by 18.1% during the fourth quarter, Holdings Channel reports. The firm owned 35,706 shares of the company’s stock after purchasing an additional 5,481 shares during the period. Fermata Advisors LLC’s holdings in enVVeno Medical were worth $108,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hohimer Wealth Management LLC acquired a new stake in enVVeno Medical in the third quarter valued at approximately $286,000. Maven Securities LTD bought a new stake in shares of enVVeno Medical in the 3rd quarter worth $295,000. Westside Investment Management Inc. increased its stake in enVVeno Medical by 128.0% in the 3rd quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock valued at $297,000 after buying an additional 49,613 shares during the last quarter. Corsair Capital Management L.P. purchased a new stake in shares of enVVeno Medical during the third quarter valued at approximately $390,000. Finally, Geode Capital Management LLC increased its position in enVVeno Medical by 7.8% in the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after buying an additional 10,902 shares during the last quarter. Institutional investors and hedge funds own 34.71% of the company’s stock.

enVVeno Medical Stock Up 3.5 %

NVNO opened at $3.29 on Friday. The company has a market capitalization of $57.71 million, a price-to-earnings ratio of -2.55 and a beta of 1.21. The firm has a 50-day moving average price of $3.13 and a 200-day moving average price of $4.12. enVVeno Medical Corporation has a twelve month low of $2.45 and a twelve month high of $6.97.

enVVeno Medical (NASDAQ:NVNO) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, sell-side analysts expect that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.

enVVeno Medical Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).